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We describe a rapid method for precisely measuring concentrations of anticonvulsant drugs in serum. The simple procedure, adaptable to the clinical laboratory, can be used for the routine simultaneous measurement in sera of phenobarbital, primidone, dephenylhydantoin, and (or) ethosuximide. The extraction procedure requires no solvent evaporation and gives a good yield for primidone and quantitative extraction for the other drugs. The relatively small amount of "early phenobarbital"
formed during oncolumn methylation permits a precise analysis of phenobarbital based on a single peak. Results can be made available directly, without manual measurements or calculations. 
Methods in which concentrated

Our extraction procedure differs from that reported
by Joern in the ionic strength of the NaH2PO4 used to buffer the serum. We achieve a 57% extraction of primidone with 3 mol/liter buffer, but only 43% extraction with 1 mol/liter buffer. The larger peak area obtained by using the more concentrated buffer permits more precise quantitation of primidone. We markedly improved the precision of phenobarbital analysis by minimizing the degradation of phenobarbital during flash-heater methylation.
A single large N,N-dimethylphenobarbital peak permits quantitation that is simpler and more precise than by other methods.
Materials and Methods
Extraction Procedure
One milliliter of serum, 1 ml of 3 mol/liter NaH2PO4 dissolved in methanol/water (1/9 by vol), and 10 ml of ether/toluene (3/7 by vol) containing 2.50 zg of 5-(4-methylphenyl)-5-phenylhydantoin per milliliter as an internal standard are placed in a 15-ml, glass-stoppered, round-bottom tube. The mixture is shaken vigorously by hand for 30 s, then centrifuged (1000 X g, 2 mm). After centrifugation, about 9 ml of the organic (upper) phase is decanted into a 12-ml, glass-stoppered, conical tube. The column is conditioned before use for 1.5 h at 310 #{176}C without carrier-gas flow and overnight at 280 #{176}C with a nitrogen flow of 40 ml/min. Injector temperature is 350 #{176}C, detector temperature 300 #{176}C. Carrier gas is nitrogen at a flow rate of 40 ml/min. The automatic sampler (Hewlett-Packard, Avondale, Pa. 19311) is equipped with a l-Ml syringe (Hamilton Co., Reno, Nev. 89502) Temperature programming permits the simultaneous determination of four drugs relative to a single internal standard (Figure 1) . Column temperature is held at 150 #{176}C for 1 mm, programmed from 150 to 260 #{176}C at 20 #{176}C/min, and held at 260 #{176}C for 2 mm.
We have recently adapted the method to an automatic data-reduction system (Hewlett-Packard Model 5830). (A) trimelhylanilinium hydroxide exiract injected into a 2-mm injection port liner. P8/s EPB, PS = .35, CV = 6.1 (n = 10); (B) tetramethylammonium hydroxide extract Injected into a 2 mm injection port liner. PS/i EPS. PB = .58, CV = 2.6 (n = 6); (C) tetramethylammonium hydroxide extract Injected into a 1 mm Injection port liner. PB/i EPB. PB = .80, CV = 1.6(n = 7)
Results
Calibration.
Calibration
The blank found for drug-free sara is diminished by conditions that diminish EPB tract from serum to which a mixture of the four drugs had been added at 4-h intervals for 16 h (i.e., five runs).
The resulting CVs were: 1.6% for 43.3 g/ml ethosuximide, 1.1% for 23.0 Mg/ml phenobarbital, 1.2% for 9.6 g/ml primidone, and 1.4% for 13.4 g/ml diphenylhydantoin.
In samples held for 24 h there is a significant decrease in the response for primidone.
Precision.
The inclusion of multiple internal standards for specific anticonvulsants has been suggested as a means of enhancing the repeatability of drug-concentration measurements (6). For results to be reported directly as concentrations in serum with the data-reduction system, each drug must be quantitated on the basis of a comparison with the area of a single internal-standard peak. We obtain excellent precision by this method and eliminate manual calculations. We determined the overall precision of the method during one month by daily extraction of a serum pool to which a mixture of the four drugs had been added. The CVs were 3.0% for 42.0 Mg/rnl ethosuximide, 2.2% for 22.7
Mg/rnl phenobarbital, 2.4% for 9.5 g/ml primidone, and 2.8% for 13.7 g/ml diphenylhydantoin (n = 22).
Carry-over.
Carry-over, expressed as a percentage of the previously injected sample, varied from 4% for diphenylhydantoin to 1% for phenobarbital. This is of little importance, because a clinically significant increase in apparent concentrations owing to carry-over requires a previous injection representing extremely toxic concentrations.
The sample following such a sample should be repeated.
Degradation. Degradation of phenobarbital during flash heater methylation has been examined by several authors (3-5). In our experience, samples extracted into tetramethylammonium hydroxide give a larger proportion of N,N-dimethylphenobarbital than those extracted into trimethylanilinium hydroxide (Figure 3,  A and B) . The proportion of dimethyl derivative formed is increased if the inner diameter of the portion of the glass column into which the sample is injected is decreased (Figure 3, B and C) . This effect may be due to the increased linear flow rate through the smaller volume of the narrow injection port liner. Reduction of the early phenobarbital peak permits a more precise calculation of phenobarbital concentration based on a substantially larger N,N-dimethylphenobarbital peak. Use of a single peak to quantitate phenobarbital permits automatic data reduction, so that concentrations in serum are directly calculated.
